Acquisition by Tony Goodman of 42000 shares of Adial Pharmaceuticals at 1.35 subject to Rule 16b-3

ADIL Stock  USD 1.10  0.08  6.78%   
About 61% of Adial Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Adial Pharmaceuticals stock suggests that many investors are alarmed at this time. Adial Pharmaceuticals' investing sentiment shows overall attitude of investors towards Adial Pharmaceuticals.
  
Filed transaction by Adial Pharmaceuticals Director, Officer Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 42000 stock option (right to buy) at 1.35 of Adial Pharmaceuticals by Tony Goodman on 27th of March 2024. This event was filed by Adial Pharmaceuticals with SEC on 2024-03-25. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Adial Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Adial Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Adial Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Adial Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Adial Pharmaceuticals Fundamental Analysis

We analyze Adial Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adial Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adial Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Flow From Operations

Cash Flow From Operations Comparative Analysis

Adial Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Adial Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adial Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Adial Pharmaceuticals Related Equities

DMACDiaMedica Therapeutics   5.23   
0%
84.0%
VCNXVaccinex   1.50   
0%
24.0%
VCYTVeracyte   1.23   
0%
19.0%
VANIVivani Medical   0.78   
0%
12.0%
DNTHDianthus Therapeutics   0.77   
0%
12.0%
VCELVericel Corp   0.63   
0%
10.0%
DOMHDominari Holdings   1.20   
19.0%
0%
DNLIDenali Therapeutics   2.53   
41.0%
0%
EQEquillium   4.11   
66.0%
0%
VALNValneva SE   6.16   
100.0%
0%
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:
Check out Adial Pharmaceuticals Hype Analysis, Adial Pharmaceuticals Correlation and Adial Pharmaceuticals Performance.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.94)
Return On Assets
(1.04)
Return On Equity
(3.21)
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.